COVID-19 Convalescent Plasma

Kathryn Dzintars, Pharm.D., BCPS
Pediatric Dosing Author: Lisa Hutchins, Pharm.D.
COVID-19 Convalescent Plasma is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • The FDA issued an updated Emergency Use Authorization (EUA, 12/28/21) permitting the use of high-titer COVID-19 convalescent plasma only for patients who are immunosuppressed or receiving immunosuppressive therapy, whether hospitalized or ambulatory.
  • The FDA EUA specifies the following:
    • Only high titer plasma units are authorized for administration. COVID-19 convalescent plasma must be tested for anti-SARS-CoV-2 antibodies with 1 of 6 available kits (See Appendix A in 12/28/21 EUA)
    • The administration should be initiated with 1 unit (200 mL).
      • Additional convalescent plasma units may be administered based on the patient’s clinical response.
    • Physicians should consider using COVID-19 convalescent plasmas among patients with impaired humoral immunity.
    • Healthcare providers must make the FDA Fact Sheet for Patients and Parents/Caregivers available before use.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • The FDA issued an updated Emergency Use Authorization (EUA, 12/28/21) permitting the use of high-titer COVID-19 convalescent plasma only for patients who are immunosuppressed or receiving immunosuppressive therapy, whether hospitalized or ambulatory.
  • The FDA EUA specifies the following:
    • Only high titer plasma units are authorized for administration. COVID-19 convalescent plasma must be tested for anti-SARS-CoV-2 antibodies with 1 of 6 available kits (See Appendix A in 12/28/21 EUA)
    • The administration should be initiated with 1 unit (200 mL).
      • Additional convalescent plasma units may be administered based on the patient’s clinical response.
    • Physicians should consider using COVID-19 convalescent plasmas among patients with impaired humoral immunity.
    • Healthcare providers must make the FDA Fact Sheet for Patients and Parents/Caregivers available before use.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: January 14, 2022